JPRN-jRCT2080224668已完成3 期
Radium-223 Dichloride Long-term Follow-up Program
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- Male
入选标准
- •Subject was previously enrolled in a selected company sponsored feeder trial, and has received at least 1 dose of radium 223 dichloride or placebo in the feeder trial
排除标准
- •Not applicable to this follow up study
研究者
相似试验
招募中
3 期
Analysis of the efficacy and safety of Radium223 in men with advanced prostate cancerMetastatic castration resistant prostate cancer with bone metastasesCancerISRCTN12835467Ospedale Civile Spirito Santo25
进行中（未招募）
1 期
A phase II clinical trial of radium-223 activity in patients with metastatic castration-resistant prostate cancer (mCRPC) with asymptomatic progression while on abiraterone acetate or enzalutamide besides AR-V7 mutational statusPatients with mCRPC with asymptomatic progression while on abiraterone acetate or enzalutamideMedDRA version: 19.0Level: PTClassification code 10036909Term: Prostate cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 19.0Level: LLTClassification code 10076506Term: Castration-resistant prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001888-36-ESMedica Scientia Innovation Research (MedSIR ARO)52
进行中（未招募）
1 期
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks.EUCTR2013-003046-17-GBBayer HealthCare AG44
进行中（未招募）
1 期
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks.Castration Resistant Prostate cancer patients with bone metastasesMedDRA version: 16.1Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2013-003046-17-SEBayer HealthCare AG40
进行中（未招募）
1 期
A study investigating the safety of radium-223 dichloride, given as a 50kBq/kg dose every four weeks to patients with castration-resistant prostate cancer that has spread to bone, who have already been treated with a course of six doses of radium-223 dichloride 50kBq/kg every four weeks.Castration Resistant Prostate cancer patients with bone metastasesMedDRA version: 19.0Level: LLTClassification code 10036916Term: Prostate cancer stage DSystem Organ Class: 100000004864EUCTR2013-003046-17-DEBayer AG40